Followers | 26 |
Posts | 1899 |
Boards Moderated | 0 |
Alias Born | 06/15/2007 |
Sunday, June 28, 2020 9:14:19 AM
I don't know if they have intellectual patent rights yet (or if they can)but when this news gets around to people that manufacture things
..well am I safe to say that it may rocket this stock?
GLTA
$ $SINT $$$
https://www.biorxiv.org/content/10.1101/2020.06.19.159970v1.full.pdf
https://www.otcmarkets.com/filing/conv_pdf?id=14236955&guid=KdTFUeTzDw1Kk3h
From FORM 424B5
(Prospectus filed pursuant to Rule 424(b)(5))
Filed 06/24/20:
The Company has received positive testing results from an independent study that demonstrate the potential anti-viral properties of our silicon nitride. The
results suggest that silicon nitride may be useful in the reduction of the spread of COVID-19. The study results demonstrated that our unique grade of silicon
nitride inactivates the SARS-CoV-2 virus within a minute after exposure and has the potential to decrease the risk of viral disease spread on surfaces.
Studies have shown that coronavirus spreads between humans when an infected person coughs or sneezes. Also, the virus can remain active on a variety of
commonly touched surfaces for hours to days. We believe that by incorporating our unique composition of silicon nitride into products such as face masks,
and personal protective equipment, it is possible to manufacture surfaces that inactivate viral particles, thereby limiting the spread of the disease. [color=red] We
envision incorporating our silicon nitride into high-contact surfaces such as medical equipment, screens, countertops, and doorknobs in locations where viral[/color]
persistence is a concern, such as homes, casinos, and cruise ships. This believe this anti-viral discovery will open many new opportunities for us. In
composites, coatings, and mixtures, silicon nitride has maintained its antibacterial and osteogenic properties, even at small fractions. We believe that
incorporating our material into a variety of commonly-touched surfaces may discourage viral spread, and contribute to global health by reducing the risk of
disease
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM